| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
American Cancer Society, National Home Office, Atlanta, Georgia 30329-4251 [H. S. F.]; Departments of Preventive Medicine [H. S. F., R. M-C., G. A. C., D. O. S., B. E. H.] and Urology [G. A. C.], University of Southern California Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California 90033-0800; and Cancer Etiology Program, Cancer Research Center of Hawaii, University of Hawaii, Honolulu, Hawaii 96813 [L. N. K.]
We conducted a nested case-control study to evaluate whether polymorphisms in two genes involved in estrogen metabolism, CYP17 and HSD17B1, were useful in developing a breast cancer risk model that could help discriminate women who are at higher risk of breast cancer. If polymorphisms in these genes affect the level of circulating estrogens, they may directly influence breast cancer risk. The base population for this study is a multiethnic cohort study that includes African-American, Non-Latina White, Japanese, Latina, and Native Hawaiian women. For this analysis, 1508 randomly selected controls and 850 incident breast cancer cases of the first four ethnic groups who agreed to provide a blood specimen were included (76 and 80% response rates, respectively). The CYP17 A2 allele and the HSD17B1 A allele were considered "high-risk" alleles. Subjects were then classified according to number of high-risk alleles. After adjusting for age, weight, and ethnicity, we found that carrying one or more high-risk alleles increases the risk of advanced breast cancer in a dose-response fashion. The risk among women carrying four high-risk alleles was 2.21 [95% confidence interval (CI), 0.98–5.00; P for trend = 0.03] compared with those who carried none. This risk was largely limited to women who were not taking hormone replacement therapy (relative risk, 2.60; 95% CI, 0.95–7.14) and was most pronounced among those weighing 170 pounds or less (RR, 3.05; 95% CI, 1.29–7.25). These findings suggest that breast cancer risk has a strong genetic component and supports the theory that the underlying mechanism of "complex traits" can be understood using a multigenic model of candidate genes.
This article has been cited by other articles:
|
|
 |
|
  M. KULENDRAN, M. SALHAB, and K. MOKBEL Oestrogen-Synthesising Enzymes and Breast Cancer Anticancer Res, April 1, 2009; 29(4): 1095 - 1109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Gaudet, S. Chanock, A. Dunning, K. Driver, L. A. Brinton, J. Lissowska, B. Peplonska, P. Pharoah, and M. Garcia-Closas HSD17B1 Genetic Variants and Hormone Receptor-Defined Breast Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 2008; 17(10): 2766 - 2772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Plourde, C. Manhes, G. Leblanc, F. Durocher, M. Dumont, O. Sinilnikova, I. BRCAs, and J. Simard Mutation analysis and characterization of HSD17B2 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer J. Mol. Endocrinol., April 1, 2008; 40(4): 161 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. W. Setiawan, F. R. Schumacher, C. A. Haiman, D. O. Stram, D. Albanes, D. Altshuler, G. Berglund, J. Buring, E. E. Calle, F. Clavel-Chapelon, et al. CYP17 Genetic Variation and Risk of Breast and Prostate Cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3) Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2237 - 2246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Millikan, A. Hummer, C. Begg, J. Player, A. R. de Cotret, S. Winkel, H. Mohrenweiser, N. Thomas, B. Armstrong, A. Kricker, et al. Polymorphisms in nucleotide excision repair genes and risk of multiple primary melanoma: the Genes Environment and Melanoma Study Carcinogenesis, March 1, 2006; 27(3): 610 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S. Feigelson, D. G. Cox, H. M. Cann, S. Wacholder, R. Kaaks, B. E. Henderson, D. Albanes, D. Altshuler, G. Berglund, F. Berrino, et al. Haplotype Analysis of the HSD17B1 Gene and Risk of Breast Cancer: A Comprehensive Approach to Multicenter Analyses of Prospective Cohort Studies Cancer Res., February 15, 2006; 66(4): 2468 - 2475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Millikan, J. S. Player, A. R. deCotret, C.-K. Tse, and T. Keku Polymorphisms in DNA Repair Genes, Medical Exposure to Ionizing Radiation, and Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., October 1, 2005; 14(10): 2326 - 2334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C J Fabian, B F Kimler, M S Mayo, and S A Khan Breast-tissue sampling for risk assessment and prevention Endocr. Relat. Cancer, June 1, 2005; 12(2): 185 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lurie, G. Maskarinec, R. Kaaks, F. Z. Stanczyk, and L. Le Marchand Association of Genetic Polymorphisms with Serum Estrogens Measured Multiple Times During a 2-Year Period in Premenopausal Women Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1521 - 1527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. C. Onland-Moret, C. H. van Gils, M. Roest, D. E. Grobbee, and P. H.M. Peeters Cyp17, Urinary Sex Steroid Levels and Breast Cancer Risk in Postmenopausal Women Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 815 - 820. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tsuchiya, H. Nakao, T. Katoh, H. Sasaki, M. Hiroshima, T. Tanaka, T. Matsunaga, T. Hanaoka, S. Tsugane, and T. Ikenoue Association between endometriosis and genetic polymorphisms of the estradiol-synthesizing enzyme genes HSD17B1 and CYP19 Hum. Reprod., April 1, 2005; 20(4): 974 - 978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. K. Dunn, D. L. Wickerham, and L. G. Ford Prevention of Hormone-Related Cancers: Breast Cancer J. Clin. Oncol., January 10, 2005; 23(2): 357 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Travis, M. Churchman, S. A. Edwards, G. Smith, P. K. Verkasalo, C. R. Wolf, H. Wolf, and T. J. Key No Association of Polymorphisms in CYP17, CYP19, and HSD17-B1 with Plasma Estradiol Concentrations in 1,090 British Women Cancer Epidemiol. Biomarkers Prev., December 1, 2004; 13(12): 2282 - 2284. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Sharp, A. H. Cardy, S. C. Cotton, and J. Little CYP17 Gene Polymorphisms: Prevalence and Associations with Hormone Levels and Related Factors. A HuGE Review Am. J. Epidemiol., October 15, 2004; 160(8): 729 - 740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. W. Setiawan, S. E. Hankinson, G. A. Colditz, D. J. Hunter, and I. De Vivo HSD17B1 Gene Polymorphisms and Risk of Endometrial and Breast Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2004; 13(2): 213 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bretsky, C. A. Haiman, S. Gilad, J. Yahalom, A. Grossman, S. Paglin, D. Van Den Berg, L. N. Kolonel, R. Skaliter, and B. E. Henderson The Relationship between Twenty Missense ATM Variants and Breast Cancer Risk: The Multiethnic Cohort Cancer Epidemiol. Biomarkers Prev., August 1, 2003; 12(8): 733 - 738. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Pike, L. N. Kolonel, B. E. Henderson, L. R. Wilkens, J. H. Hankin, H. S. Feigelson, P. C. Wan, D. O. Stram, and A. M. Y. Nomura Breast Cancer in a Multiethnic Cohort in Hawaii and Los Angeles: Risk Factor-adjusted Incidence in Japanese Equals and in Hawaiians Exceeds that in Whites Cancer Epidemiol. Biomarkers Prev., September 1, 2002; 11(9): 795 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S. Feigelson, R. McKean-Cowdin, and B. E. Henderson Concerning the CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis Mutagenesis, September 1, 2002; 17(5): 445 - 446. [Full Text] [PDF]
|
|
|
|
|
|
Z. Ye and J. M. Parry Concerning the CYP17 MSPA1 polymorphism and breast cancer risk: a meta-analysis Mutagenesis, September 1, 2002; 17(5): 447 - 448. [Full Text] [PDF]
|
|
|
|
|
|
Z. Ye and J. M. Parry The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis Mutagenesis, March 1, 2002; 17(2): 119 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. McKean-Cowdin, L. N. Kolonel, M. F. Press, M. C. Pike, and B. E. Henderson Germ-line HER-2 Variant and Breast Cancer Risk by Stage of Disease Cancer Res., December 1, 2001; 61(23): 8393 - 8394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gunnarsson, B. M. Olsson, and O. Stal Abnormal Expression of 17{beta}-Hydroxysteroid Dehydrogenases in Breast Cancer Predicts Late Recurrence Cancer Res., December 1, 2001; 61(23): 8448 - 8451. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
